The overlooked side of UM insourcing: medical drugs
Published:
November 12, 2026

Why this matters: Health plans are bringing utilization management (UM) in-house to take back control, but medical benefit drugs tend to come up less in that conversation. This blog covers why they belong in the insourcing plan, how to phase them in, and what plans need to get right.
Handing UM to an outside vendor once looked like the fastest way to scale. Now more health plans are bringing it back in-house to own their clinical strategy, their data, and the experience clinicians have with prior authorization (PA).
That conversation tends to focus on medical services. But what about the drugs? Medical benefit drugs are the specialty and high-cost therapies administered in a clinic or infusion center, billed under the medical benefit, and often reviewed against complex clinical criteria.
Why medical drugs, and why now?
Many plans have wanted more control over their UM programs for years. What’s changed is that the tools to run it well in-house—including for complex medical drugs—are now available. Three things make the case.
Control over decisions
When drug review sits with a vendor, so do the criteria and much of the data on how decisions get made. In-house, plans apply their own policies and see utilization and cost trends for these drugs directly.
Technology that scales with the work
Medical drugs bring more to manage every year. Specialty trend ran 9.6% in 2024, and cost per claim rose in the medical benefit while it fell in the pharmacy benefit, according to PSG’s 2025 Artemetrx report. The FDA approved 46 novel drugs in 2025, above its long-run average. Manual review is hard to scale against that. Automation and clinical AI can now apply plan criteria to routine requests and surface the right evidence for complex ones, so in-house teams can keep pace without adding manual work for every new request.
A defined timeline
The proposed CMS-0062 rule would bring medical benefit drugs into the same electronic PA requirements CMS-0057 set for medical services, with a proposed compliance date of October 1, 2027. Plans building that infrastructure for medical services are already partway there, but those that delegate drug review still answer to CMS if a vendor falls behind on the deadline.
How do medical drugs fit into a phased rollout?
Moving medical drug UM in-house from a delegated arrangement comes with a tradeoff: you gain greater control, but you also take on the complexity yourself. A phased rollout helps keep that complexity manageable.
Our approach is to bring UM in-house specialty by specialty. Plans start with high-volume, routine services that are simpler to manage, then add complex areas as their teams and processes mature. That way, each phase builds on the experience, staffing, and workflows from the one before.
Medical drugs sit at the complex end of that path. Many are specialty therapies with detailed clinical criteria, high costs per claim, and evidence that keeps evolving. For plans that already run medical services UM in-house, that makes them a natural next phase.
Three decisions shape it:
- Who reviews: Most plans already have nurses, intake staff, and physicians on their UM teams. For drugs, the gap is usually PharmD review alongside them.
- Whose criteria: A previous vendor likely applied its own criteria. Plans choose between internal policies, licensed criteria, or policies codified into the workflow with a partner.
- What comes first: Phase in by line of business or drug category, so staffing grows with volume. Put compliance processes for CMS-0057 and state requirements in place before automation.
What does drug review need to work in-house?
Once staffing and policy decisions are set, the day-to-day work comes down to review. Medical drug requests carry different data and criteria than medical services. Depending on the plan’s policies, they can also pass through more than one clinical reviewer, especially for high-cost drugs or complex dosing. Three things keep that work moving.
1. Drug-specific criteria: Criteria for medical drugs often incorporate dosing guidelines, preferred products, site of care requirements, and other considerations to support appropriate, cost-effective treatment. Health plans need to evaluate which elements to include in their UM programs, and their readiness to operationalize them.
2. Review built for the whole clinical team: Insourcing medical drugs often means adding PharmDs to a UM team built around RNs and MDs. That adds complexity to factor in early: which requests need pharmacist review, how it fits alongside nurse and physician review, and how to staff for it as volume grows. Cohere Health supports PharmD review in the same UM workflow and brings the expertise to help plans set it up.
3. Scale with clinicians in control: Requests that clearly meet criteria can be approved automatically. For the rest, clinicians get the evidence, member context, and current medications without digging through the record, and the final call stays theirs.
What's the next move?
If you’ve already brought medical services UM in-house, you’ve done the hard part. The clinical team, the workflows, and much of the infrastructure are already in place. If medical drugs have been on your insourcing list, the next step is closer than it may seem.
New specialty therapies keep arriving, costs keep climbing, and CMS-0062 would put a date on electronic PA for medical drugs. The real decision now is how much to bring in, and how fast.
Cohere Health already helps plans take back control of UM in-house. Now Cohere Rx extends Cohere Intake™, Cohere Decision™, and Cohere Review™ to medical drug UM on the Cohere Unify™ platform, the same clinical intelligence platform that supports workflows from PA to payment integrity. Plans can fold specialty, high-cost, and provider-administered drug PA into the same workflow as medical services, giving clinicians a single place to submit both. Cohere Health runs inside the plan, so your clinicians work directly with the AI, apply your criteria, and make the final call—backed by our clinical and operational expertise.
Ready to answer the drug question for your plan?
See how Cohere Rx supports medical drug UM or talk with an expert.
Available For Download
Written by
Cohere
Health
Cohere Health’s clinical intelligence and operations platform and agentic AI-powered solutions connect health plans’ strategic goals and providers’ needs, optimizing the speed, cost, and quality of care. With an enterprise approach that streamlines payer-provider decision-making across the care continuum–including policy, prior authorization, payment accuracy, and more–the company improves collaboration and reduces burden, resulting in up to 9x ROI and 94% provider satisfaction. Cohere Health is recognized on TIME’s World’s Top HealthTech Companies 2026 list, on the 2026 Inc. 5000 list, and by numerous industry analysts.
Stay ahead with expert insights on transforming utilization management and payment integrity—delivered straight to your inbox.


